Zero-Sales Biotechs May Damage Your Financial Health

, , , , , , , , , ,

China's biotech unicorns are chasing a big prize. Landing it may prove elusive. BeiGene Ltd. raised $903 million in a secondary listing in Hong Kong last week. The company’s market value has swelled to $9.4 billion since its 2016 initial public offering on the Nasdaq, despite the firm being at the “clinical stage”– a euphemism for having sales. Competitor […]

Read More...

Blue Apron is having a really bad day

, , ,

Things are not going so well for Blue Apron this morning after reporting its second-quarter earnings (its first earnings report ever), and the stock is crashing as a result of it. The companys stock is down more than 14 percent on the earnings report, which came in pretty mixed compared to what Wall Street wanted. […]

Read More...